AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years of delivering oral PrEP and how to move faster, more strategically, and with greater coordination to maximize the impact of injectable CAB for PrEP.
Translating Scientific Advance into Public Health Impact
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP
Statement on the Dapivirine Ring for Women: Call for Accelerated Global Access
This statement, from a coalition of advocates, applauds the WHO for its ongoing support and its 2021 recommendation of the dapivirine vaginal ring as an additional prevention option for women. The advocates call on funders, country governments and community leaders to sustain their support for the ring’s introduction and rollout in African countries where it is needed and for prompt regulatory reviews. And they call on HIV programs to integrate the ring, and collaborate with communities on the design of those programs.
Consultation with FP/SRH Stakeholders on the Dual Prevention Pill
This report summarizes and reports next steps from an AVAC and FP2030 convened consultation with family planning (FP) and sexual and reproductive health (SRH) stakeholders. The aim of the consultation was to understand stakeholders’ unique perspectives on the Dual Prevention Pill (DPP), a daily oral pill that prevents HIV and pregnancy. The consultation helped to elevate questions and issues to consider as DPP introduction plans are refined and that can also inform the development and delivery of future multi-purpose prevention technologies (MPTs).
What Matters Right Now for Rolling Out the Ring and Injectable PrEP?
The HIV field has two new approved prevention options waiting in the wings, the dapivirine vaginal ring and injectable cabotegravir as PrEP. Until now, daily oral PrEP, first approved in 2012, has been the only drug-based strategy for HIV prevention.
So here we are: research has shown safety and efficacy for both the ring and injectable cabotegravir. Now it’s time to take the next steps to deliver these options and translate advances in science into real impact on the epidemic.
At AVAC, we’ve been calling for coordinated planning to introduce and rollout new products, while expanding access to existing options. These efforts must learn from the mistakes of the past, especially lessons from rolling out oral PrEP.
In this episode of PxPulse, Linda-Gail Bekker from South Africa’s Desmond Tutu Health Foundation and Lillian Mworeko from the International Community of Women Living with HIV East Africa (ICWEA) join host Jeanne Baron and AVAC’s Executive Director Mitchell Warren to discuss innovative models for scale-up and delivery. Taking the right steps now could mean HIV prevention options fulfill their life-saving, epidemic-ending potential, and to do so requires working faster and more efficiently than ever before.
We dive into what lessons the field has learned, what’s still off-track, and the steps advocates, policy makers, drug makers and funders should each take right now to turn efficacious options into effective choices.
Resources
Dapivirine Vaginal Ring
Cabotegravir
Ring and CAB
AVAC’s Strategic Plan 2022-2026
AVAC’s strategic framework is grounded in a multi-layered approach that carefully considers all of the components needed to achieve the organization’s vision, capitalize on its key strengths, and ensure that AVAC is poised to make an impact on the issues it cares most about over the next five years, and beyond.
The vision describes the world we are striving for. The mission describes what AVAC does in service to achieving this vision. The strategic pillars outline the objectives and approaches that AVAC will take over the next five years to achieve its mission and vision. The strategic pillars are supported by AVAC’s core values—the principles by which we work—as well as a set of key enablers.
Advocate, Translate, Catalyze: For HIV prevention and health equity
In this document, we look at the actions we are taking and those that as a field we all need to take to transform prevention “options” developed through research into prevention “choices” for people that can save lives and help end epidemics. This work is critical, and it is shared – just as we developed our strategic plan and EDI statement in partnership with so many, so too will we move this work forward, together.
Seven Global Civil Society Priorities for the 2021-2025 President’s Emergency Plan for AIDS Relief (PEPFAR) Strategy
As the largest funder of HIV/AIDS programming in the world, PEPFAR has the power and opportunity to move the dial. A large number of AVAC partners and other civil society organizations in Eastern and Southern Africa heard the call for comments and suggestions for the new strategy—and responded here with seven key priorities.
BioPIC Adaptable Product Introduction Framework
This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in terms of downstream product introduction needs. Stakeholders involved in early product development may also consider leveraging some of the activities included to anticipate future needs.
HIV Vaccine Research: Building on the Lessons from COVID
Building on the lessons of COVID, HIV vaccine advocates can mobilize for an HIV vaccine research and access agenda. This two-page document gives suggested messaging.
Breaking the Bottlenecks to COVID-19 Vaccine Access
This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.